Quince Therapeutics (NASDAQ:QNCX) Now Covered by Analysts at Maxim Group

Maxim Group began coverage on shares of Quince Therapeutics (NASDAQ:QNCX) in a research report sent to investors on Thursday,Benzinga reports. The brokerage issued a buy rating and a $6.00 price target on the stock.

Several other analysts have also commented on the stock. Rodman & Renshaw initiated coverage on shares of Quince Therapeutics in a report on Tuesday, October 29th. They issued a “buy” rating and a $11.00 price objective for the company. RODMAN&RENSHAW raised shares of Quince Therapeutics to a “strong-buy” rating in a research report on Tuesday, October 29th. Finally, EF Hutton Acquisition Co. I raised shares of Quince Therapeutics to a “strong-buy” rating in a research report on Tuesday, October 22nd.

Quince Therapeutics Stock Performance

Shares of NASDAQ:QNCX traded up $0.09 during trading on Thursday, hitting $1.63. 224,850 shares of the company were exchanged, compared to its average volume of 222,129. The company has a debt-to-equity ratio of 0.29, a current ratio of 6.15 and a quick ratio of 6.15. Quince Therapeutics has a 52-week low of $0.51 and a 52-week high of $1.79. The company has a market cap of $70.54 million, a PE ratio of -1.22 and a beta of 0.71. The stock has a 50 day moving average of $0.89 and a 200 day moving average of $0.82.

Quince Therapeutics (NASDAQ:QNCX) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.18) earnings per share (EPS) for the quarter.

Insiders Place Their Bets

In other Quince Therapeutics news, CEO Dirk Thye acquired 77,500 shares of the business’s stock in a transaction dated Thursday, August 29th. The stock was purchased at an average price of $0.69 per share, with a total value of $53,475.00. Following the transaction, the chief executive officer now directly owns 766,941 shares in the company, valued at approximately $529,189.29. The trade was a 0.00 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other news, CEO Dirk Thye bought 77,500 shares of the stock in a transaction that occurred on Thursday, August 29th. The shares were bought at an average price of $0.69 per share, for a total transaction of $53,475.00. Following the purchase, the chief executive officer now owns 766,941 shares in the company, valued at $529,189.29. This represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, President Charles S. Ryan purchased 48,387 shares of the firm’s stock in a transaction on Tuesday, August 20th. The stock was bought at an average price of $0.65 per share, for a total transaction of $31,451.55. Following the purchase, the president now owns 122,461 shares in the company, valued at approximately $79,599.65. This represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders purchased 158,887 shares of company stock valued at $105,609. Company insiders own 16.80% of the company’s stock.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.